This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Glossary
- 5′NT=
- 5′-nucleotidase;
- AC=
- adenylate cyclase;
- ACh=
- acetylcholine;
- ADK=
- adenosine kinase;
- AMP=
- adenosine monophosphate;
- ATP=
- adenosine triphosphate;
- CCL=
- chemokine ligand;
- CGRP=
- calcitonin gene related peptide;
- COX-2=
- cyclooxygenase-2;
- EctoN=
- ectonucleotidases;
- ENT=
- equilibrative nucleoside transporters;
- ERK1,2=
- extracellular signal regulated kinase 1,2;
- G=
- guanine nucleotide binding protein;
- GABA=
- γ-aminobutyric acid;
- GIRK=
- G-protein gated inward rectifying potassium channels;
- IL=
- interleukin;
- NGF=
- nerve growth factor;
- NMDA=
- N-methyl-d-aspartate;
- NO=
- nitric oxide;
- PD=
- Parkinson disease;
- PLA2=
- phospholipase A2;
- PLC=
- phospholipase C;
- PLD=
- phospholipase D;
- SNc=
- substantia nigra pars compacta;
- VLPO=
- ventrolateral preoptic area.
Adenosine is a ubiquitous chemical messenger that modulates cellular activity in both the CNS and peripheral organs.1–5 Adenosine levels in the brain extracellular space increase dramatically during metabolically stressful conditions, such as ischemia, seizures, or trauma. Adenosine, acting via different receptors, modulates excitability in the CNS2–4 and has a role in mechanisms of seizure susceptibility,5,6 sleep induction,7 basal ganglia function,8 pain perception,9 cerebral blood flow,10 and respiration.11 Adenosine receptors are inhibited by caffeine and other methylxanthines and provide a potential target for treatment of cerebral ischemia,12 seizures,13 pain,9 Parkinson disease (PD),8,14 and Huntington disease.15 There are several excellent reviews on recent experimental findings and insights into adenosine signaling in the CNS,1–6,8 and on adenosine as a potential therapeutic target in neurologic disorders.5–7,12–15
ADENOSINE SIGNALING IN THE NERVOUS SYSTEM
There is tight and dynamic regulation of adenosine levels in the nervous system.1–5 All cell types contribute to the accumulation of extracellular adenosine (figure). Extracellular concentrations of adenosine are determined by the interplay between the activity of intracellular and extracellular enzymes involved in adenosine metabolism and the transport of adenosine across the cell membrane. Metabolic stress triggers the dephosphorylation of adenosine triphosphate (ATP) and formation of adenosine monophosphate (AMP), which is converted to adenosine by 5′-nucleotidase. Adenosine is then released from cells by facilitated diffusion via nucleoside transporters, the best characterized being the equilibrative nucleoside transporters (ENT).16 Adenosine may also be produced by the extracellular metabolism of ATP via a cascade of ectonucleases.2–4 The primary route of adenosine metabolism is adenosine kinase (ADK), which is expressed primarily in astrocytes (figure). The concentration of extracellular adenosine increases dramatically in the setting of metabolic stress such as hypoxia, ischemia, trauma, or seizures.2–5,12 Transport from the astrocyte is the primary source of …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
